Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, complement-mediated diseases, cancers, and addictive and compulsive disorders. Omeros’ lead MASP-2 inhibitor narsoplimab, targeting the lectin pathway of complement, is currently pending US marketing approval for the treatment of hematopoietic stem cell transplant-associated microangiopathy (TA-TMA) and is also in late-stage clinical development programs for IgA nephropathy, COVID-19, and atypical hemolytic uremic syndrome. OMS1029 is a long-acting MASP-2 antibody in Phase 1, and a MASP-2 inhibitor for oral delivery is advancing toward the clinic. OMS906 is an antibody against MASP-3, the key activator of the alternative pathway of complement, and is progressing in clinical programs for paroxysmal nocturnal hemoglobinuria (PNH) and complement 3 (C3) glomerulopathy.
Legend
Available Timeslot
Scheduled Appointment
Personal Appointments
Appointment Request
Blocked Timeslot
Restricted Timeslot